Bio-Rad Laboratories (BIO-B) FCF Margin (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of FCF Margin data on file, last reported at 13.19% in Q1 2026.

• FCF Margin for Q1 2026 came in at 13.19%, down 312.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 13.79% (down 20.0% YoY), and the FY2025 annual result was 14.5%, up 322.0% from the prior year.
• FCF Margin fell to 13.19% in Q1 2026 per BIO-B's latest filing, from 17.18% in the prior quarter.
• Over five years, FCF Margin peaked at 18.99% in Q3 2024 and troughed at 2.44% in Q3 2022.
• A 5-year average of 9.41% and a median of 9.22% in 2023 frame the typical range for FCF Margin.
• The sharpest annual moves came in 2022 and 2025: FCF Margin sank 2864 bps in 2022, then jumped 1147 bps in 2025.
• A 5-year view of FCF Margin shows it stood at 6.13% in 2022, then dropped by 7 bps to 5.69% in 2023, then surged by 114 bps to 12.18% in 2024, then surged by 41 bps to 17.18% in 2025, then declined by 23 bps to 13.19% in 2026.
• Business Quant data shows BIO-B's FCF Margin at 13.19% in Q1 2026, 17.18% in Q4 2025, and 13.66% in Q3 2025.